The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced attention to the diagnosis of Hepatitis D. However, migratory fluxes from HDV endemic areas, fostered by labour-forces globalization, are increasingly reconstituting the reservoir of HDV in the country and hepatitis D has not yet vanished in native Italians but will remain an important medical issue for several years to come. As the epidemiologic and clinical features of HDV infection in migrant communities are largely unknown and the features of native Italians with long standing HDV infections have not been updated, this project intends to establish the contemporary epidemiological and medical context of HDV in immigrants in Italy and to determine the clinical characteristics and needs of the residual cohort of native HDV Italians, through the analysis of all HDV cases recruited in 12 months in a coordinated network of 35 Italian medical centers. The data will provide an appraisal of the burden of hepatitis D in the country and of its impact on the National Health System. They will present the paradigm of the current trend of HDV infection in high-income countries in the world.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Demographic characteristics of HDV-infected patients
Timeframe: 1 year
Epidemiologic characteristics of HDV-infected patients
Timeframe: 1 year
Serum alanine aminotransferase concentration values in HDV-infected patients
Timeframe: 1 year
Blood platelet count in HDV-infected patients
Timeframe: 1 year
Serum albumin concentration values in HDV-infected patients
Timeframe: 1 year
Serum total bilirubin concentration values in HDV-infected patients
Timeframe: 1 year
Serum anti-liver-kidney microsomal antibodies titer in HDV-infected patients
Timeframe: 1 year
Proportion of patients with detectable HDV RNA among seropositive anti-HDV patients
Timeframe: 1 year
Serum HDV RNA levels in HDV-infected patients
Timeframe: 1 year
Proportion of HDV genotypes among patients with detectable HDV RNA
Timeframe: 1 year
Proportion of patients with detectable HBV DNA among seropositive anti-HDV
Timeframe: 1 year
Serum HBV DNA levels in HDV-infected patients
Timeframe: 1 year
Proportion of HBV genotypes among patients with detectable HBV DNA
Timeframe: 1 year
HBsAg concentration levels in HDV-infected patients
Timeframe: 1 year
HBcrAg concentration levels in HDV-infected patients
Timeframe: 1 year
Proportion of patients with liver cirrhosis among seropositive anti-HDV
Timeframe: 1 year
Liver stiffness values in HDV-infected patients
Timeframe: 1 year
Proportion of patients with hepatocellular carcinoma among seropositive anti-HDV
Timeframe: 1 year
Proportion of patients treated with antiviral therapy among seropositive anti-HDV
Timeframe: 1 year